- Home
- USEA vs NCEL Comparison
USEA vs NCEL Comparison
Compare USEA & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | NCEL |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Greece | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 19.4M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | USEA | NCEL |
|---|---|---|
| Price | $2.49 | $2.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 79.8K | 7.2K |
| Earning Date | 11-13-2026 | 09-18-2026 |
| Dividend Yield | ★ 8.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.16 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $1.83 |
| 52 Week High | $3.20 | $5.12 |
Technical Indicators
Market Signals| Indicator | USEA | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 41.44 |
| Support Level | $2.46 | $1.95 |
| Resistance Level | $2.63 | $3.32 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 35.98 | 20.51 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.